Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

Inhibitors of VEGF (vascular endothelial growth factor)/VEGFR2 (vascular endothelial growth factor receptor 2) are commonly used in the clinic, but their beneficial effects are only observed in a subset of patients and limited by induction of diverse relapse mechanisms. We describe the up-regulation...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Transl Med
Autors principals: Allen, Elizabeth, Jabouille, Arnaud, Rivera, Lee B., Lodewijckx, Inge, Missiaen, Rindert, Steri, Veronica, Feyen, Kevin, Tawney, Jaime, Hanahan, Douglas, Michael, Iacovos P., Bergers, Gabriele
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5554432/
https://ncbi.nlm.nih.gov/pubmed/28404866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aak9679
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars